{"id":5661,"date":"2014-11-26T23:11:20","date_gmt":"2014-11-26T22:11:20","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=5661"},"modified":"2014-11-26T23:16:23","modified_gmt":"2014-11-26T22:16:23","slug":"i-prossimi-blockbusters-merck-bms-astrazeneca-roche","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/i-prossimi-blockbusters-merck-bms-astrazeneca-roche\/","title":{"rendered":"The next blocKbusters from Merck, BMS, AstraZeneca, Roche"},"content":{"rendered":"<p><a href=\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2014\/11\/pharmaceutical-executive.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-5666 alignnone\" alt=\"pharmaceutical executive nov 2014\" src=\"http:\/\/www.fedaiisf.it\/wp-content\/uploads\/2014\/11\/pharmaceutical-executive.jpg\" width=\"437\" height=\"243\" \/><\/a><\/p>\n<ul>\n<li>In its sales forecast report <strong><span style=\"color: #ff0000;\">Keytruda<\/span><\/strong> Of <strong>Roche<\/strong>, EvaluatePharma expects revenue of <strong>$4.06 billion<\/strong> by 2020. In September, pembrolizumab received accelerated approval from the FDA for the treatment of melanoma. Now the Company is working on a drug for non-small cell lung cancer (NSCLC), and other indications.<\/li>\n<\/ul>\n<ul>\n<li><span style=\"color: #ff0000;\"><strong>Opdivo<\/strong><\/span> Of <strong>BMS extension<\/strong> it&#039;s the most valuable drug in development right now, says Lisa Urquhart, director of the editorial team at Evaluate, EP Vantage. \u201cThe data from the studies is showing some impressive progress in overall survival from the disease. \u201cEvaluatePharma forecasts potential sales of Opdivo a<strong> 6 billion dollars<\/strong> by 2020.<\/li>\n<li><span style=\"color: #ff0000;\"><strong>\u00a0Genentech<\/strong><\/span> Of <strong>Roche<\/strong>, is still found in study trials for NSCLC, melanoma, RCC, and bladder cancer. The company received the breakthrough designation for this latest indication. EvaluatePharma puts revenue at <strong>$2.93 billion<\/strong>i by 2020.<\/li>\n<li><strong>AstraZeneca<\/strong> is on the run with the drug <span style=\"color: #ff0000;\"><strong>MedImmune<\/strong><\/span> PD-L1 MEDI-4736, targeting NSCLC. A small study of 18 people showed a 28% response of MEDI-4736 in combination with CTLA-4tremelimumab antibodies. medi-4736 sell forecast close to <strong>$1.1 billion<\/strong> by 2019.<\/li>\n<\/ul>\n<p>Read all about <a href=\"http:\/\/images2.advanstar.com\/PixelMags\/pharma-executive\/pdf\/2014-11.pdf\" target=\"_blank\" rel=\"noopener\">Pharmaceutical Executive\u00a0<\/a> November 2014<\/p>","protected":false},"excerpt":{"rendered":"<p>Nella sua relazione sulle\u00a0 previsioni di vendita Keytruda di Roche,\u00a0EvaluatePharma prevede un fatturato di 4,06 miliardi dollari entro il 2020. Nel mese di settembre pembrolizumab aveva ricevuto l&#8217;approvazione accelerata dalla FDA per il trattamento del melanoma. Ora l&#8217;Azienda si sta occupando di un farmaco contro il cancro polmonare non a piccole cellule (NSCLC), e di &hellip;<\/p>","protected":false},"author":5,"featured_media":5668,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/5661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=5661"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/5661\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/5668"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=5661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=5661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=5661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}